The Longevity Reporter have published an excellent article about MMTP. We talk with them about the urgent need for advocacy as well as the disconnect between bench and bedside and where animal data fits into that chain.
Good science relies on being open to new findings and changing ones approach based on new information. The subject of Senolytics is another such example where it has the potential to be beneficial but could also prove to be detrimental too. This is one of the reasons why the MMTP is testing Senolytics in robust lifespan testing to explore the possibilities of this new medical approach and to see if it has positive or negative effects or perhaps both.